8 148
manuscript (eg, employment/af
fi
liation, grants or funding, consultan-
cies, honoraria, stock ownership or options, expert testimony, royalties,
or patents
fi
led, received, or pending), are the following: None.
Funding/Support and role of the sponsor:
Orion Corporation (Finland)
and Bayer (Germany) funded personnel and equipment costs for this
study.
Acknowledgments:
The authors wish to thank Mary Bowden and Virginia
Yago who helped performing the in vivo studies.
Appendix A. Supplementary data
Supplementary material related to this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.08.012.
References
[1]
Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resis- tance in prostate cancer at the molecular level. Eur Urol 2015;67: 470 – 9.
[2]
Lorente D, Mateo J, Perez-Lopez R, de Bono JS, Attard G. Sequencing of agents in castration-resistant prostate cancer. Lancet Oncol 2015;16:e279 – 92.
[3]
Barbieri CE, Chinnaiyan AM, Lerner SP, Swanton C, Rubin MA. The emergence of precision urologic oncology: a collaborative review on biomarker-driven therapeutics. Eur Urol 2017;71: 237 – 46.
[4]
Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer thera- pies. Sci Rep 2015;5:12007.
[5]
Massard C, Penttinen HM, Vjaters E, et al. Pharmacokinetics, antitumor activity, and safety of odm-201 in patients with chemo- therapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol 2016;69:834 – 40.
[6]
Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 2014;15: 975 – 85.
[7]
Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013;3:1020 – 9.
[8]
Lallous N, Volik SV, Awrey S, et al. Functional analysis of androgen receptor mutations that confer anti-androgen resistance identi fi ed in circulating cell-free DNA from prostate cancer patients. Genome Biol 2016;17:10.
[9]
Wyatt AW, Azad AA, Volik SV, et al. Genomic Alterations in cell-free DNA and enzalutamide resistance in castration-resistant prostate cancer. JAMA Oncol 2016;2:1598 – 606.
[10]
Paul N, Carabet LA, Lallous N, et al. Cheminformatics modeling of adverse drug responses by clinically relevant mutants of human androgen receptor. J Chem Inf Model 2016;56:2507 – 16.E U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) 4
–
8
8